(Updated) Nanotechnology: Understanding the Tiny Particles That May Save a Life

By Nathalie Walker, Guest Writer

Could nanotechnology—the study of tiny matter ranging in size from 1 to 200 nanometers—be the future of cancer treatment?

Although it is a relatively new field in cancer research, nanotechnology is not new to everyday life. Have you ever thought about the tennis ball you’ve thrown with your dog at the park and wondered what it is made of? Nanotechnology is used to make the tennis ball stronger. A coating of clay nanoparticles was added to the core of

Tags: 

(Updated) Fort Detrick Gate Hours Change Effective April 10

The Fort Detrick gate hours will change beginning Friday, April 10.

The new hours were recently provided by the U.S. Army Garrison (USAG), Fort Detrick. NCI will continue to work with the USAG to address questions that may arise. Note that no changes have been made for facilities outside of the Fort Detrick campus (e.g., the Advanced Technology Research Facility).

Tags: 

(Updated) NCI Fiscal 2016 Bypass Budget Proposes $25 Million for Frederick National Lab

By Nancy Parrish, Staff Writer; image by Richard Frederickson, Staff Photographer

The additional funding requested for Frederick National Laboratory for Cancer Research (FNLCR) in the Fiscal 2016 Bypass Budget was $25 million, or approximately 3.5 percent of the total additional funding request of $715 million.  

Officially called the Professional Judgment Budget, the Bypass Budget is a result of the National Cancer Act of 1971, which authorizes NCI to submit a budget directly to the president, to send to Congress. With a focus on NCI’s research priorities and areas of cancer research with potential for investment, the Bypass Budget specifies additional funding, over and above the current budget, that is needed to advance

Tags: 

FDA Approves Immunotherapy for a Cancer that Affects Infants and Children

Gloved hand holding a vial

By Frank Blanchard, Staff Writer

The U.S. Food and Drug Administration (FDA) recently approved dinutuximab (ch14.18) as an immunotherapy for neuroblastoma, a rare type of childhood cancer that offers poor prognosis for about half of the children who are affected. The National Cancer Institute’s (NCI) Biopharmaceutical Development Program (BDP) at the Frederick National Laboratory for Cancer Research produced ch14.18 for the NCI-sponsored clinical trials that proved the drug’s effectiveness against the disease.

Tags: 

Platinum Publications as of February 26, 2015

Platinum Publications are selected from articles by NCI at Frederick scientists published in 42 prestigious science journals. This list represents new publications generated from PubMed as of the date shown above.

Articles designated as Platinum Highlights are noteworthy articles selected by Dr. Craig Reynolds, associate director, National Cancer Institute, from among the most recently published Platinum Publications.

Tags: 

Pages